rxstat › Drug prices › Fondaparinux
Fondaparinux (Arixtra) price in Canada
No current shortage
Fondaparinux 2.5 mg/0.5ml solution costs about $9.86 per billed unit (often a pen or vial) on public drug plan price lists across 2 provinces, before the pharmacy's dispensing fee. The brand (Arixtra) lists at $13.46.
Fondaparinux has no current shortage reported in Canada. It has been in shortage before; the history is below.
Price by province
| Strength and form | AB | MB | ON | NS | NL |
|---|---|---|---|---|---|
| 2.5 mg/0.5ml Solution | $9.86/unitbrand $13.46 | $9.86/unit | $11.19/unitbrand $13.46 | – | $24.40/unitbrand $29.35 |
| 7.5 mg/0.6ml Solution | $17.50/unitbrand $23.89 | $18.14/unit | $18.14/unit | – | $19.77/unitbrand $26.04 |
| Plan coverage | Covered | Price list | Covered | Not covered | Price list |
What you'll pay at the pharmacy
These are the prices public drug plans list for the drug itself. At the counter, pharmacies add a dispensing fee and in some provinces a markup, so paying cash costs more, and for cheap generics the fee is often more than the drug. If you have a public or private plan, your share depends on its deductible and co-pay. In Ontario, the plan pays only up to the lowest interchangeable price ($11.19 per unit for 2.5 mg/0.5ml).
Listed products by province
Alberta: 4 products
- Fondaparinux Sodium Injection 2.5 mg/0.5ml Solution · DRL
- Arixtra 2.5 mg/0.5ml Solution · APC
- Fondaparinux Sodium Injection 7.5 mg/0.6ml Solution · DRL
- Arixtra 7.5 mg/0.6ml Solution · APC
Manitoba: 4 products
- Fondaparinux Sodium Injection 2.5 mg/0.5ml Solution · DRL
- Arixtra 2.5 mg/0.5ml Solution · ASH
- Fondaparinux Sodium Injection 7.5 mg/0.6ml Solution · DRL
- Arixtra 7.5 mg/0.6ml Solution · ASH
Ontario: 4 products
- Fondaparinux Sodium Injection 2.5 mg/0.5ml Solution · Dr. Reddy's Laboratories Inc.
- Arixtra 2.5 mg/0.5ml Solution · Aspen Pharma Trading Limited
- Fondaparinux Sodium Injection 7.5 mg/0.6ml Solution · Dr. Reddy's Laboratories Inc.
- Arixtra 7.5 mg/0.6ml Solution · Aspen Pharma Trading Limited
Nova Scotia: 4 products
- Arixtra 2.5 mg/0.5ml Solution · APN
- Fondaparinux Sodium Injection 2.5 mg/0.5ml Solution · RCH
- Arixtra 7.5 mg/0.6ml Solution · APN
- Fondaparinux Sodium Injection 7.5 mg/0.6ml Solution · RCH
Newfoundland and Labrador: 4 products
- Fondaparinux Sodium Injection 7.5 mg/0.6ml Solution · DRL
- Fondaparinux Sodium Injection 2.5 mg/0.5ml Solution · DRL
- Arixtra 7.5 mg/0.6ml Solution · ASP
- Arixtra 2.5 mg/0.5ml Solution · ASP
Shortage status
Reports by product
What's happening
There are no active shortage reports for Fondaparinux. Health Canada has 7 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.
Fondaparinux is classified under “ANTITHROMBOTIC AGENTS” (ATC B01AX).
Recent changes
- No changes recorded yet.
Common questions
How much does Fondaparinux cost in Canada?
Fondaparinux 2.5 mg/0.5ml solution costs about $9.86 per billed unit (often a pen or vial) on public drug plan price lists across 2 provinces, before the pharmacy's dispensing fee. The brand (Arixtra) lists at $13.46.
Is Fondaparinux covered by provincial drug plans?
On the public plans' own lists: Alberta: covered; Manitoba: price list; Ontario: covered; Nova Scotia: not covered; Newfoundland and Labrador: price list. "Special approval" means the plan covers it only for some patients, on a request from the prescriber. "Price list" means the province publishes its price but not its coverage.
When will Fondaparinux be back in stock in Canada?
Fondaparinux has no active shortage; supply is normal per Health Canada reports.
Why is Fondaparinux in shortage?
It isn't currently. Past reports and their reasons are listed above.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Related drugs (antithrombotic agents)
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.